Effects of vitamin D supplementation on endothelial function:a systematic review and meta-analysis of randomised clinical trials by Hussin, Azizah Mat et al.
1  
 
 
 
 
 
 
1 Title: Effects of vitamin D supplementation on endothelial function: a systematic review and 
2 meta-analysis of randomised controlled trials 
3 
4 Authors: Azizah Mat Hussin1,2#, Ammar W. Ashor1,3#, Inez Schoenmakers4, Tom Hill5, John 
5 C. Mathers1, Mario Siervo1,4* 
6 
7 1Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, 
8 Campus for Ageing and Vitality, Newcastle on Tyne, NE4 5PL, UK 
9 2Institute of Medical Science Technology- Universiti Kuala Lumpur, Malaysia 
10 3College of Medicine, University of Al-Mustansiriyah, Baghdad, Iraq 
11 4MRC Human Nutrition Research, Elsie Widdowson Laboratory, 120 Fulbourn Road, 
12 Cambridge, CB1 9NL 
13 5School of Agriculture, Food and Rural Development, Newcastle University, Newcastle upon 
14 Tyne, UK 
15 
16 Running title: Vitamin D supplementation and endothelial function 
17 
18 Keywords: vitamin D, nitric oxide, flow-mediated dilation, forearm blood flow, pulse wave 
19 velocity, cardiovascular risk 
20 
21 *Corresponding author: Mario Siervo (email: mario.siervo@newcastle.ac.uk) 
22 #Equal contribution 
23 
24 The material presented in this manuscript is original and it has not been submitted for 
25 publication elsewhere while under consideration for European Journal of Nutrition. 
26 
27 
28 Abstract word count: 247 
29 Total word count: 3657 
30 References: 68 
31 Tables: 3 
32 Figures: 1 
33 OSM: 1 
34 
 
35 PROSPERO Database registration: CRD42014009668, http://www.crd.york.ac.uk/prospero/ 
 
36 
2  
37 Abstract 
 
38 Background: In addition to regulating calcium homeostasis and bone health, vitamin D 
 
39 influences vascular and metabolic processes including endothelial function (EF) and    insulin 
 
40 signalling. This systematic review and meta-analysis of randomized clinical trials (RCTs) 
 
41 was conducted to investigate the effect of vitamin D supplementation on EF and    to examine 
 
42 whether the effect size was modified by health status, study duration, dose, route of vitamin 
 
43 D administration, vitamin D status (baseline and post-intervention), body mass index  (BMI), 
 
44 age and type of vitamin D. 
 
45 Methods: We searched the Medline, Embase, Cochrane Library, and Scopus databases  from 
 
46 inception until March 2015 for studies meeting the following criteria: 1) RCT with adult 
 
47 participants, 2) vitamin D administration alone, 3) studies that quantified EF using commonly 
 
48 applied  methods  including  ultrasound,   phlethysmography,   applanation  tonometry,   laser 
 
49 Doppler. 
 
50 Results: Sixteen articles reporting data for 1177 participants were included. Study duration 
 
51 ranged from 4 to 52 weeks. The effect of vitamin D on EF was not significant (SMD: 0.08, 
 
52 95%CI:-0.06, 0.22, P=0.28). Subgroup analysis showed a significant improvement of EF in 
 
53 diabetic subjects (SMD: 0.31, 95%CI: 0.05, 0.57, P=0.02). A non-significant trend was found 
 
54 for diastolic blood pressure (β=0.02; P=0.07) and BMI (β=0.05; P=0.06). 
 
55 Conclusions:  Vitamin  D  supplementation  did  not  improve  EF.  The  significant  effect of 
 
56 vitamin D in  diabetics  and  a tendency for an association  with  BMI may indicate  a role  of 
 
57 excess adiposity and insulin resistance in modulating the effects of vitamin D on vascular 
 
58 function. This remains to be tested in future studies. 
 
59 
 
60 
 
61 
3  
62 1. Introduction 
 
63 Cardiovascular diseases (CVDs) are a major public health concern and contribute to >30% of 
 
64 overall mortality worldwide[1]. The pathogenesis of CVDs is multifactorial and a critical step 
 
65 in the onset and advancement of CVDs is the formation of atherosclerotic lesions [2]. One  of 
 
66 the earliest stages of the atherosclerosis process is the impairment of endothelial function 
 
67 (EF) [3]. 
 
68 The   pathophysiology   of   endothelial   dysfunction   is   complex   and   involves    multiple 
 
69 mechanisms including over-production of reactive oxidative species, inflammatory cytokines 
 
70 and pro-atherogenic lipoproteins together with an imbalance between vaso-dilating and vaso- 
 
71 constricting molecules. Impairment of vasodilatation may be due to reduced    bio-availability 
 
72 of nitric oxide (NO), which is produced by the endothelial cells and which is involved in 
 
73 multiple physiological processes including vasodilation, inflammation and platelet 
 
74 aggregation[4]. 
 
75 Vitamin D is a pro-hormone which is mostly known for its involvement in the regulation of 
 
76 calcium homeostasis and bone remodelling [5]. However, vitamin D is also essential for 
 
77 several non-musculoskeletal functions including regulation of vascular tone, gluco-insular 
 
78 homeostasis and immunity [5]. Vitamin D receptors (VDRs) are expressed in several   tissues 
 
79 notably endothelial cells, vascular smooth muscle cells and    cardiomyocytes  [6]. The active 
 
80 form  of  vitamin  D  (1α,25-dihydroxyvitamin  D3,  1,25(OH)2D3)  is  a  direct transcriptional 
 
81 regulator of endothelial NO synthase [7]. A recent study has shown that VDR mutant mice 
 
82 have lower NO bioavailability leading to endothelial dysfunction, increased arterial  stiffness, 
 
83 increased aortic impedance, structural  re-modelling of the  aorta, and  impaired systolic   and 
 
84 diastolic  heart  function  [8].  However,  observational  studies  evaluating  the  association of 
 
85 vitamin D with CVD risk have reported mixed results. A significant inverse relationship 
 
86 between low vitamin D status, as assessed by serum 25-hydroxy vitamin D (25-OHD) and 
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87 increased  risk  of  major  cardiovascular  events  and  chronic  diseases  such  as   myocardial 
 
88 infarction (MI), stroke, hypertension and type 2 diabetes has been reported [9-11], but this 
 
89 has not been confirmed in other cohorts [12, 13]. These discrepant results may be ascribed  to 
 
90 the differences between study designs and phenotypic characteristics of study participants 
 
91 including 1) duration of follow up, 2) cut-off values for the definition of deficient vitamin   D 
 
92 status,  3)  diagnostic  criteria  for  the  identification  and  classification  of      cardiovascular 
 
93 outcomes, 4) confounding factors (i.e., diet, sun exposure, seasonality, physical activity)  and 
 
94 5) health status of the participants in the cohorts [14]. Randomised controlled trials (RCTs) 
 
95 examining the effects of vitamin D supplementation on EF have also reported contradictory 
 
96 results; whilst some studies have reported improvement in EF [15-17] others have observed 
 
97 no effect of vitamin D supplementation [18-30]. A recent meta-analysis has showed a non- 
 
98 significant  effect  of  vitamin  D  supplementation  on  changes  in  flow  mediated     dilation 
 
99 measured by ultrasound after post-occlusion hyperaemia. The study showed that effects   was 
 
100 greater in short studies (<16 weeks) and in subjects with raised systolic and diastolic blood 
 
101 pressure (BP)[31]. 
 
102 The method for the assessment of EF in humans depends on the availability of resources  and 
 
103 equipment, technical and research expertise and, most importantly, by the research    question 
 
104 under  investigation.  The  most  commonly  used  methods  to  measure  dynamic     vascular 
 
105 responses are: i) ultrasound to assess the increase in diameter of large arteries following post- 
 
106 occlusive hyperaemia, ii) phlethysmography to assess changes in forearm blood flow   during 
 
107 infusion of pharmacological agents targeting endothelial-related mechanisms (e.g. 
 
108 acetylcholine or sodium  nitroprussiate)   and iii) applanation tonometry by measuring    pulse 
 
109 wave velocity (PWV) of peripheral arteries [32]. 
 
110 We aimed to conduct a systematic review and meta-analysis of RCTs investigating the  effect 
 
111 of supplemental vitamin D on EF. The secondary aim of the study was to determine   whether 
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112 the  effect  size  was  modified  by  health  status,  study  duration,  dose,  route  of  vitamin D 
 
113 administration, baseline vitamin D status and changes in 25-OHD after supplementation, 
 
114 body mass index (BMI), age and type of vitamin D (vitamin D2 or vitamin D3). 
 
115 2. Methods 
 
116 The present systematic review was conducted according to the Cochrane guidelines [33] and 
 
117 it is reported according to PRISMA guidelines [34]. 
 
118 2.1 Literature search 
 
119 Four databases (Medline, Embase, Scopus, and Cochrane Library) were used to search for 
 
120 articles from inception until March 2015. In addition, a manual search of reference lists of 
 
121 relevant reviews and articles included in the systematic review was performed. The search 
 
122 was conducted based on pre-defined search terms [Ergocalciferol OR Cholecalciferol OR 
 
123 vitamin D OR Vitamin D2 OR vitamin D3 OR 25(OH)D] And [Endotheli* OR Endotheli* 
 
124 dysfunction  OR  FMD  or  Hyperaemia  OR  Plethysmography  OR  Flow  mediated        OR 
 
125 Endothelial-dependent OR  Vasomotor  or  Vasoacti*  OR  Blood  flow  OR  Brachial   OR 
 
126 Vasodilat* OR Dilat* OR Vascular resistance OR Pulse Wave OR Augmentation index    OR 
 
127 Arterial  stiffness  OR  Digital  volume  pulse  OR  Pulse  amplitude  tonometry  OR  Arterial 
 
128 compliance]. 
 
129 2.2 Study selection 
 
130 The following criteria were applied to identify articles to be included in this systematic 
 
131 review and meta-analysis: 1) RCTs (no further exclusion criteria were applied in relation to 
 
132 study design or blinding); 2) studies involving adults aged 18 years or more and no exclusion 
 
133 criteria  were  applied  for  health  status,  smoking  history  or  body  size;  3)  vitamin  D 
 
134 administered alone i.e. not combined with other drugs or nutritional interventions; studies 
 
135 were not excluded on the basis of the dose, duration of follow up, route of administration of 
 
136 vitamin D or type of administration (i.e. tablet, capsule, solution or as fortified food) and type 
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137 of assay used for the determination of 25-OHD concentrations; 4) studies reporting changes 
 
138 in EF measured by ultrasound, venous-occlusion phlethysmography, photo 
 
139 phlethysmography,   pulse   wave   velocity,   pulse   amplitude   tonometry,   laser     Doppler 
 
140 flowmetry; 5) no language or time restrictions were applied in searching the databases. 
 
141 Two investigators (AMH, MS) independently screened the titles and abstracts of the   articles 
 
142 to evaluate eligibility for inclusion. If consensus was reached, articles were either excluded or 
 
143 moved to the next stage (full-text). If consensus was not reached the articles was moved to 
 
144 the full-text stage. The full-texts of the selected articles were appraised critically to determine 
 
145 eligibility for inclusion in the systematic review. Disagreements were resolved by  discussion 
 
146 among the authors until the consensus was reached. 
 
147 2.3 Data extraction and quality assessment 
 
148 The following information was extracted from the eligible articles: 1) authors, journal  details 
 
149 and    year of publication; 2) participants (total number, male/female ratio, age, health status); 
 
150 3)   study   characteristics   (country,   design,   inclusion/exclusion   criteria,   description   of 
 
151 measurement  protocols;  4)  vitamin  D  intervention  (type,  formulation,  dose,  duration  of 
 
152 follow up, route of administration); 5) EF measurement (instrument, position, duration of 
 
153 cuffing) and 6) circulating concentrations of vitamin D before and after intervention. 
 
154 In addition, we adopted the modified Jadad score to assess the risk of bias of the included 
 
155 studies; possible scores ranged from 0 to 5 and a score of ≤ 3 indicates high risk while a score 
 
156 of > 3 indicates low risk of bias[35]. 
 
157 2.4 Statistical analysis 
 
158 Serum concentrations of 25-OHD given in ng/mL were converted to nmol/L (1 ng/mL=2.496 
 
159 nmol/L)[36]. Several methods were used to assess EF in humans including flow mediated 
 
160 dilation (FMD), forearm blood  flow (FBF), pulse wave  analysis  (PWA) and  laser  Doppler 
 
161 (LD) with the results obtained from these methods reported on different scales. Therefore,  to 
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162 allow comparison of effect sizes between studies, standardised mean differences (SMDs) 
 
163 were used as a summary statistic. SMD is estimated from the difference between the mean 
 
164 outcome  values  of  the  intervention  and  control  groups  divided  by  the  pooled   standard 
 
165 deviation (SD) of the outcome values; this converts the estimated effect to SD units. SMD  of 
 
166 0.2, 0.5 and 0.8 represent small, medium and large effect sizes, respectively[37]. In  addition, 
 
167 different methods were frequently used in the same trial to assess EF, as shown in Table 1, 
 
168 and therefore this lack of independence of the EF measurement in each trial was taken into 
 
169 consideration in the derivation of the pooled effect size. Statistical analyses    were performed 
 
170 by using Comprehensive meta-analysis software (version 2, Biostat, Englewood, New Jersey, 
 
171 USA). Data synthesis, including calculation of effect sizes with 95% confidence intervals, 
 
172 was accomplished by employing a random-effects model using inverse variance weighting. 
 
173 Forest plots were generated for graphical presentation of the effect of supplemental vitamin D 
 
174 on EF. For this purpose, the mean and SD of the EF measure before and after the intervention 
 
175 period (for both vitamin D intervention and control) were extracted and used in the   analysis. 
 
176 For studies that reported changes in EF at two or more time-points (e.g. acute and chronic 
 
177 effects  of  vitamin  D  supplementation),  the  last  EF  measurement  was  used  in  the meta- 
 
178 analysis. Data not provided in the main text or tables were extracted from the figures. 
 
179 Subgroup analyses were undertaken to investigate the variables which    may have influenced 
 
180 the effects of supplementation on EF. These factors included: health status, type (vitamin   D2 
 
181 or D3) and the frequency of administration (single dose, daily-weekly or monthly) of  vitamin 
 
182 D supplementation. Random effect meta-regression analyses were used to determine whether 
 
183 participant baseline characteristics (age, BMI, systolic and diastolic blood pressure,   baseline 
 
184 concentration of 25-OHD) influence the effect of vitamin D supplementation (vitamin D2     or 
 
185 D3)  on  EF.  Furthermore,  meta-regression  analyses  were  conducted  to  investigate       the 
 
186 influence of other factors  including vitamin D dose,  baseline 25-OHD, change in    25-OHD 
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187 concentration after supplementation, duration of interventions, sample size and quality   score 
 
188 (Jadad score) on the effect of vitamin D supplementation on EF. 
 
189 Heterogeneity between studies was evaluated using Cochrane Q statistics; P > 0.1 indicates 
 
190 significant heterogeneity. The I2  test was also used to evaluate consistency between studies 
 
191 where a value < 25% indicates low risk of heterogeneity, 25-75% indicates moderate risk    of 
 
192 heterogeneity,   and   >75%   indicates   high   risk   of   heterogeneity[38].   The   evidence of 
 
193 publication bias was assessed by visual inspection of the funnel plots and by the Egger’s 
 
194 regression test[39]. 
 
195 3. Results 
 
196 3.1 Search results 
 
197 The process of screening and selection of studies is summarised in Figure S1 of the online 
 
198 supplementary  material. The primary search of the four databases produced 4159    articles 
 
199 after  removal  of  duplicates.  After  title  and  abstract  screening,  22  full-text  papers  were 
 
200 retrieved  for  further  evaluation.  Additionally,  one  study was  found  by  manual searching 
 
201 references of the relevant reviews and studies. Examination of the full text of 23 articles 
 
202 yielded 16 studies which were eligible to be included in this systematic review and meta- 
 
203 analysis. One trial [25] included two independent arms supplementing different vitamin D 
 
204 doses which resulted in 17 independent interventions entered in the final meta-analysis. 
 
205 3.2 Studies characteristics 
 
206 The total number of participants from the 16 studies included in this systematic review was 
 
207 1177 (607 females; 570 males) with median of 73 (range 34 -159) participants per study. The 
 
208 median age was 63.2 (range 30-77) years. All RCTs included in the meta-analysis were 
 
209 parallel, double-blind, placebo-controlled trials. The duration of the trials ranged from 4 
 
210 weeks to 52 weeks (Table 1). 
9  
211 Three studies  investigated the effect  of vitamin D in  healthy participants  [16, 18,  40],  two 
 
212 studies were conducted in    patients with chronic kidney disease (CKD) [19, 22], four studies 
 
213 in diabetics [15, 17, 25, 30], six studies in patients with CVDs [20, 23, 24, 26, 28, 29] and 
 
214 one study in patients with HIV [21]. All trials supplemented vitamin D orally. Trials however 
 
215 utilised different forms of supplementation including tablets [20, 23, 30], solution[17, 19, 24- 
 
216 26, 28, 40], capsules [15, 16, 21, 22] and fortified biscuits [18]. The majority of the trials 
 
217 utilised vitamin D3  with daily doses varying from 1000IU/day [15] to 5000IU/day [30]. 
 
218 Several methods were used to assess EF in the included trials. The most commonly used 
 
219 methods  were  FMD  [16-19,  21,  22,  25,   29,  30], PWV  [18-20,  22,  29,  30,  40]   and 
 
220 augmentation index (AIx) [15, 18, 20, 24]. Other methods include laser Doppler flowmetry 
 
221 [40]  and digital volume pulse [28]  (Table 1). 
 
222 3.3 Qualitative analysis 
 
223 Three  of  the  studies  included  in  the  present  systematic  review  reported  a      significant 
 
224 improvement in EF in response to vitamin D administration [15, 17, 41] whereas the other 13 
 
225 studies reported no effect of supplementation [18-30]. Ten studies described the methods of 
 
226 randomisation  [18-23,  25,  27,  28,  30]  and  five  studies  stated  the  methods  of allocation 
 
227 concealment [20, 21, 25, 27, 28]. The drug history of the participants was reported by all 
 
228 except three studies [15, 16, 27]. With the exception of two studies [16, 19], all other   studies 
 
229 reported, and described, participant dropout. The quality of the included studies ranged   from 
 
230 3 to 5 (Jadad score) and eleven studies had a low risk of bias (Jadad score ≥4) (Table 1). 
 
231 3.4 Meta-analysis 
 
232 Meta-analysis   of  the  16   studies   (1177  participants)  showed   that,   overall,   vitamin  D 
 
233 supplementation did not improve EF (SMD: 0.08, 95%CI: -0.06, 0.22, P=0.28) (Figure 1). 
 
234 The effect  of supplemental  vitamin D on post-occlusive vasodilation  of  the brachial   artery 
 
235 was not significant (FMD%, N=10, +0.27%, 95%CI: -0.36, 0.91, P=0.39, Table S1,   Online 
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236 Supplementary  Material).  Heterogeneity  between  studies  was  not  significant  (Q=21.7, 
 
237 I2=26.4%, P=0.15). Subgroup analysis showed that vitamin D supplementation improved  EF 
 
238 significantly in  participants  with  type  2  diabetes  (N=5,  SMD:  0.31,  95%CI:  -0.05, 0.57, 
 
239 P=0.02)   (Table   2).   This   was   confirmed   by   the   significant   effect   of   vitamin     D 
 
240 supplementation in type 2 diabetic on changes in FMD% (N=4, +0.81%, 95%CI: 0.005, 1.61, 
 
241 P=0.04,  Table  S1,  Online  Supplementary  Material).  The  response  of  EF to vitamin D 
 
242 supplementation   was   not   significantly   modified   by   type   of   vitamin   D,   method  of 
 
243 administration, baseline 25-OHD concentrations or baseline health status    of the participants 
 
244 (Table 2). Meta-regression analyses demonstrated a weak, positive effect of BMI (β: 0.05, 
 
245 SE: 0.02, P=0.06) and of baseline diastolic blood pressure (β: 0.02, SE: 0.01, P=0.07) in 
 
246 modifying the effect of vitamin D supplementation on EF (Table 3). BMI did not modify  the 
 
247 association between type 2 diabetes and EF (N=6, β: 0.04, SE: 0.04, P=0.23) whereas    lower 
 
248 baseline 25-OHD concentrations were associated with a greater effect size in type 2   diabetic 
 
249 participants  (N=6,  β:  -0.02,  SE:  0.01,  P=0.03)  (Figure   S3,   Online      Supplementary 
 
250 Material). The dose of vitamin D was not associated with significant changes in EF (Table 3 
 
251 and Figure S4, Online Supplementary Material) 
 
252 3.5 Publication bias 
 
253 Visual inspection of the funnel plot showed modest evidence of asymmetric distribution of 
 
254 the effect size ((Figure S2 of the online supplementary material), which was confirmed 
 
255 formally by the lack of significance of the Egger’s test (P=0.08). 
 
256 4. Discussion 
 
257 Overall, our meta-analysis demonstrated no effect of vitamin D supplementation on EF. In 
 
258 addition, baseline vitamin D and change in vitamin D concentration after supplementation 
 
259 were not associated with effects of vitamin D supplementation on EF. However, vitamin D 
 
260 supplementation resulted in a significant improvement in EF in patients with diabetes and 
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261 there was a positive trend towards greater effects of vitamin D on EF with increasing baseline 
 
262 BMI and diastolic blood pressure. 
 
263 Several putative mechanisms could explain the positive effects of vitamin D on EF in some 
 
264 population groups, particularly in those at higher cardiovascular risk. Vitamin D is    involved 
 
265 in  the regulation  of endothelial  cell-dependent  vasodilation  which may be mediated by the 
 
266 effect of vitamin D metabolites on the renin angiotensin-aldosterone system, a hormonal 
 
267 system that regulates blood pressure and fluid balance. A low plasma 25OHD predisposes  to 
 
268 up-regulation of the renin-angiotensin system, smooth muscle proliferation and favours a pro- 
 
269 inflammatory state which can increase the risk of hypertension and left ventricle  hypertrophy 
 
270 [42]. The improvement in EF through vitamin D supplementation could also be mediated   by 
 
271 the local effects of vitamin D metabolites on calcium metabolism in vascular smooth   muscle 
 
272 cells and on the release of inflammatory cytokines which may affect vascular contractility 
 
273 [43]. Vascular smooth muscle and endothelial cells express VDR as well    as 1α-hydroxylase 
 
274 [44], allowing for autocrine production of 1,25(OH)2D, which may act at the local level to 
 
275 modulate  the  effects  of  inflammatory  cytokines  on  the  vasculature,  such  as   decreasing 
 
276 endothelial  adhesion  molecules,  increasing  NO  production   [45]   and  reducing     platelet 
 
277 aggregation [46]. The activation of VDRs induces the transcription of a wide range of   genes 
 
278 including those coding for vascular endothelial growth factor which in turn promotes NO 
 
279 synthesis by endothelial cells. In addition, 1,25(OH)2D3 is a direct regulator of endothelial 
 
280 NO synthase [8]. 
 
281 Vitamin  D  may  also  have  beneficial  effects  on  cardio-metabolic  health  in  those     with 
 
282 hypertension [47-50], type 2 diabetes [11, 30, 51] and cardiovascular disease [52-54]. A 
 
283 meta-analysis of data from 21 prospective studied showed       an inverse association between 
 
284 vitamin D status and risk of type 2 diabetes [55]. In addition, cardiovascular disease is the 
 
285 main  cause  of  premature  mortality  and  morbidity  in  patients     with  CKD[22]. These 
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286 
 
287 
 
288 
 
289 
 
290 
 
291 inadequacy of the vitamin D dose or the advanced stage of endothelial dysfunction. 
 
292 In  the  present  meta-analysis,  we  observed  that  vitamin  D  supplementation  produced    a 
 
293 significant improvement in endothelial function in individuals with type 2 diabetes. While the 
 
294 small  number  of  trials  included  in  the  analyses  (N=4)  call  for  a  cautious  and objective 
 
295 interpretation  of  the  results,  we  believe  that  they  are  supported  by a  robust mechanistic 
 
296 rationale and provide important insights for future studies. This apparent diabetes-specific 
 
297 effect  may be  explained by several  mechanisms  including  the link  between  low   25OHD 
 
298 concentrations and i) deterioration of β-cell function, ii) dysregulation of peripheral insulin 
 
299 signalling and iii) altered glucose disposal which are typically involved in the pathogenesis of 
 
300 type 2 diabetes [11, 14, 58]. These effects appear to be supported by the greater effect of 
 
301 vitamin D supplementation on EF in type 2 diabetic patients with insufficient vitamin D 
 
302 status.  Vitamin  D  receptors  and  1-α-hydroxylase  are  expressed  in  pancreatic  β-cells and 
 
303 therefore an involvement in the regulation of insulin secretion may be expected [51]. In   turn, 
 
304 1,25(OH)2D activates transcription of the human insulin receptor gene, stimulates  expression 
 
305 of the insulin receptor [59], and enhances insulin-mediated glucose transport in vitro[60].   In 
 
306 addition, insulin secretion is a calcium-dependent process and vitamin D metabolites have 
 
307 been linked to the regulation β-cell calcium pools, which promotes insulin release [61]. The 
 
308 putative beneficial effects of vitamin D metabolites on EF may also be explained by the 
 
309 mechanistic inter-connection between the insulin and NO pathways. The activation of the 
 
310 insulin  receptor  on  the  endothelial  cells  instead  induces  a  vasodilatory  response  via the 
cardiovascular complications may be related to hypovitaminosis D [56], which may be linked 
to  the inability of  renal  mass to  convert 25OHD to  the active  form  of  vitamin D,     1,25- 
dihydroxyvitamin D[57]. However, our results did not show a significant effect of vitamin  D 
supplementation on EF in patients with CKD which could be explained by several factors 
including the small number of studies (only two trials), the short duration (8 weeks), the 
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311 activation of the phosphoinositol-3-phosphate - Akt pathway which increases NO  production 
 
312 by the enzyme endothelial nitric oxide synthase [62]. 
 
313 Our meta-regression analysis showed a trend for a greater improvement of EF in response   to 
 
314 vitamin D supplementation in participants with high BMI. Growing evidence has shown  that 
 
315 there is an inverse association between plasma 25OHD concentrations and BMI [63, 64]. 
 
316 Decreased bioavailability of vitamin D was found in obese subjects [63-65], which may be 
 
317 explained by adipose tissue sequestration and/ or volumetric dilution of 25OHD [66], and 
 
318 may  explain the tendency towards a greater effect of supplemental vitamin D on EF in 
 
319 subjects with greater adiposity. In addition, obesity and excess visceral adiposity are    closely 
 
320 associated with insulin resistance and development of type 2 diabetes which may explain  the 
 
321 almost significant effect of vitamin D supplementation on EF in obese subjects. This may 
 
322 indirectly suggest that the magnitude of the effect size of vitamin D on EF may be  correlated 
 
323 with the degree of metabolic derangement of the insulin signalling pathway. 
 
324 
 
325 
 
326 
 
327 
 
328 
 
329 
 
330 
 
331 
 
332 
 
333 
 
334 
 
335 standardization protocols in place. 
Results may have been affected by the choice of the method used to measure vitamin D 
concentrations. Unlike chromatographic methods, immunoassays do not measure vitamin  D3 
and vitamin D2 independently and this is a well-recognised limitation of immunoassays.  The 
importance  of  being  able  to  quantify  both  metabolites  of  vitamin  D  independently     is 
becoming increasingly important in recent years with the evidence that vitamin D3 is more 
biologically  active  than  vitamin  D2  [67]as  well  as  emerging  evidence  that    25(OH)D2 
concentrations are in the range of 1·5 to 10·0 nmol/l in several RCT and population based 
studies, this contributing significantly to total 25(OH)D[68]. It is also important to    point out 
that results of 25(OH)D using chromatographic methods show significant variation, mainly 
due  to  extraction  and  calibration  problems  associated  with  these  methods. Such  assay 
variation reinforces the need for all users of vitamin D assays to have appropriate QC and 
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336 Our meta-analysis has some limitations. First, the available trials had relatively small  sample 
 
337 sizes with samples sizes of <100 in about 75% of the trials included in the meta-analysis. 
 
338 Second, the variability in duration, dose and type of vitamin D supplementation, the  different 
 
339 methods used to assess EF and the diversity in participant characteristics (age, sex and  health 
 
340 status) may have introduced significant heterogeneity and have militated against   observation 
 
341 of overall  effects  of vitamin D supplementation on EF  in  our meta-analysis.  Third, not   all 
 
342 studies  adjusted  for potential  confounding factors  that may have influenced  the effect     of 
 
343 vitamin D on EF such as sun exposure, seasonality, physical activity or dietary patterns. 
 
344 Finally, most of the study participants were aged between 40 to 77 years old, thus limiting the 
 
345 applicability of the findings to other life stages. Finally, studies have used different assays  to 
 
346 measure  25-OHD  concentrations  (Immuno-Assay,  N=13;  Liquid  Chromatography   Mass 
 
347 Spectrometry,  N=3),  which  may  have  introduced  a  measurement  bias.  However,       the 
 
348 exclusion of the three studies using LC-MS from the analysis did not modify the results, 
 
349 which provides support to the importance of vitamin D status in influencing the efficacy of 
 
350 vitamin D supplementation on vascular outcomes (data not showed). 
 
351 We believe that the current evidence base is inadequate to draw firm conclusions about the 
 
352 protective role of supplemental vitamin D on EF and as a pharmaco-nutritional strategy for 
 
353 CVD  prevention.  However,  our  study  provides  important  information  on  the  effects  of 
 
354 vitamin D  supplementation  on EF and  shows that  benefit  may be  anticipated in  diabetics. 
 
355 This may indicate a potential role of insulin resistance in modulating the effects of vitamin  D 
 
356 on vascular function. This hypothesis remains to be tested in future studies. 
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Figure Legends 
 
Figure 1: Forest plot showing the effect of vitamin D supplementation on endothelial function. T2D = type 2 diabetes; CVD = cardiovascular 
disease; CKD = chronic kidney disease. Relative weight for a random model allows for small size studies contributing in a similar magnitude to 
the pooled estimate. The marker may vary in size according to the weights assigned to the different studies. The pooled effect is represented 
using a diamond. 
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Table 1: Summary of findings 
Author Country Compliance Health 
Status 
Outcome Sample 
Size 
Male 
(N) 
Age 
(years) 
BMI 
(kg/m2) 
SBP/DBP 
(mmHg) 
Vit D Dose 
(IU) 
Duration 
(Frequency) 
Formulation 
(Route) 
Baseline 
25-OHD 
(Assay) 
Assay name, company Δ 25- 
OHD 
Vit D/day 
(IU) 
Jadad 
Score 
Breslavsky et al. 
2013 [15] 
Israel Not reported T2D AI 47 22 67 29 153/74 1000 (D3) 52w 
(D) 
Capsule 
(Oral) 
29 
(IA) 
Not stated 17 1000 3 
Gepner et al. 
2012 [18] 
US Not reported Healthy PWV, 
FMD,AI 
109 0 64 26 122/72 2500 (D3) 16w 
(D) 
Biscuits 
(Oral) 
78 
(LC-MS) 
Not stated 39 2500 5 
Harris et al. 2011 
[16] 
US Not reported Healthy 
OW 
FMD 45 21 29 30 123/74 60000 (D3) 16w 
(M) 
Capsule 
(Oral) 
36 
(IA) 
Immunodiagnostic 
systems, Fountain Hills, 
AZ 
66 2000 4 
Hewitt et al. 2013 
[19] 
Australia 100% 
compliance 
CKD PWV, FMD 60 29 60 29 131/76 50000 (D3) 8w 
(WK) 
Solution 
(Oral) 
42 
(IA) 
DiaSorin Inc, Stillwater, 
MN 
42 7142 4 
Larsen et al. 2012 
[20] 
Denmark 99% 
compliance 
Ht (CVD) AI, PWV 130 35 60 28 131/77 3000 (D3) 20w 
(D) 
Tablet 
(Oral) 
57 
(IA) 
Liaison; DiaSorin, 
Saluggia, Italy 
52 3000 5 
Longenecker et 
al. 2012[21] 
US 99% 
compliance 
HIV FMD 45 35 47 27 118/80 4000 (D3) 12w 
(D) 
Capsule 
(Oral) 
19 
(IA) 
Immunodiagnostic 
Systems, Fountain Hills, 
AZ, USA 
12 4000 5 
Marckmann et al. 
2012 [22] 
Denmark 100% 
compliance 
CKD PWV, FMD 52 39 71 25 135/72 40000 (D3) 8w 
(WK) 
Capsule 
(Oral) 
28 
(LC-MS) 
(LCMSMS 1, Applied 
Biosystems, Dionex, 
Sunnyvale, California, US 
118 5714 4 
Sokol et al. 2012 
[23] 
US 99% 
compliance 
CHD RH-PAT 90 66 55 30 133/76 50000(D2) 12w 
(WK) 
Tablet 
(Oral) 
84 
(LC-MS) 
Quest Diagnostics, 
Teterboro, NJ, USA 
67 7142 3 
Stricker et al. 
2012 [24] 
Switzerland 100% 
compliance 
PAD 
(CVD) 
AI 62 38 72.9 27 136/74 100000 (D3) 4w 
(SD) 
Solution 
(Oral) 
41 
(IA) 
DiaSorin, Saluggia, Italy 19 3571 4 
Sugden et al. 
2008 [17] 
UK 100% 
compliance 
T2D FMD 34 18 65 31 141/80 100000 (D2) 8w 
(SD) 
Solution 
(Oral) 
38 
(IA) 
I.D.S., Tyne & Wear, UK 23 1785 3 
Witham 
et al. 2010 [25] 
UK 100% 
compliance 
T2D FMD 61 41 G1:65 
G2:63* 
G1:31 
G2:32 
G1:141/76 
G2:128/72 
G1:100000 (D3) 
G2:200000(D3) 
16w 
(SD) 
Solution 
(Oral) 
G1: 46 
G2: 43 
(IA) 
IDS, Boldon, UK 28 
18 
G1:892 
G2:1785 
5 
Witham 
et al. 2012 [26] 
UK 100% 
compliance 
Stroke 
(CVD) 
FMD 58 42 66 27 129/72 100000(D2) 16w 
(SD) 
Solution 
(Oral) 
38 
(IA) 
DiaSorin Ltd, Bracknell, 
UK 
12 892 3 
Witham 
et al. 2013 [27] 
UK-South 
Asian 
100% 
compliance 
Healthy FMD, PWV, 
AI, 
LD-ION 
50 0 41 27 121/78 100000 (D3) 8w 
(SD) 
Solution 
(Oral) 
27 
(IA) 
IDS Ltd UK 10 1785 5 
Witham 
et al. 2013 [28] 
UK 100% 
compliance 
MI (CVD) RHI 75 52 64 27 128/72 100000(D3) 24w 
(2M) 
Solution 
(Oral) 
47 
(IA) 
I.D.S, Bachem UK, 
Merseyside, UK 
13 1785 4 
Witham 
et al.2013 [29] 
UK 99% 
compliance 
ISH 
(CVD) 
FMD, PWV 159 82 77 28 163/78 100000(D3) 52w 
(3M) 
Solution 
(Oral) 
45 
(IA) 
Not stated 25 1190 5 
Yiu et al. 2012 
[30] 
China Not reported T2D FMD, PWV 100 66 50 25 146/81 5000(D3) 12w 
(D) 
Tablet 
(Oral) 
54 
(IA) 
I.D.S, (company not 
stated) 
92 5000 3 
N= number of subjects; OW, Overweight; IR, Insulin Resistance; AI, Augmentation Index; PWV, Pulse Wave Velocity; FMD, Flow Mediated Dilatation; RH-PAT, Reactive Hyperaemia 
Peripheral Arterial Tonometry ; RHI, Reactive Hyperaemia Index; LD-ION: Laser Doppler Iontophoresis; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; BMI= Body Mass 
Index; EF, Endothelial Function; *Different doses of vitamin D , Group 1: 100 000 IU , Group 2: 200 000 IU; w= weeks; D, daily; WK, weekly; M, monthly; SD, single dose; 2M, every 2 
months; 3M,  every 3 months. Δ= changes in vitamin D concentrations after supplementation. Vitamin D concentrations are reported in nmol/L. IA; Immuno Assay; LC-MS; liquid 
chromatography mass spectrometry. CVD= cardiovascular disease group. US= Unites States; UK= United Kingdom; Ht, Hypertension; MI, Myocardial Infraction; ISH, Isolated Systolic 
Hypertension; CHD, Coronary Heart Disease; CKD, Chronic Kidney Disease; PAD; Peripheral Arterial Disease; T2D; Type 2 Diabetes; HIV, Human Immunodeficiency Virus        
Study designs for all of the studies are parallel, double blind – placebo controlled randomized trial. I.D.S; Immunodiagnostic system. 
21  
 
 
 
 
 
Table 2: Sensitivity analysis to evaluate the influence of health status, administration of vitamin D and type of 
vitamin D supplementation on endothelial function 
vitamin D dose on the effect of 
Group No of trials or subgroup Effect size 95% CI P P between Groups 
Health status      
 Healthy 3 0.15 -0.28 0.59 0.47  
 HIV 1 0.009 -0.61 0.62 0.97  
 Diabetes 
 CKD 
 CVD 
5 
2 
6 
0.31 
0.04 
-0.05 
0.05 0.57 
-0.62 0.71 
-0.22 0.11 
0.02 
0.89 
0.51 
0.23 
Frequency of Dose Administration      
 1-3 month 4 0.17 -0.14 0.48 0.29  
 Daily-Weekly 7 0.02 -0.17 0.21 0.82 0.71 
 Single dose 6 0.09 -0.20 0.40 0.53  
Baseline 25-OHD concentration      
Normal (≥50nmol/L) 4 -0.01 -0.21 0.17 0.84 0.27 
Deficient (<50nmol/L) 13 0.13 -0.06 0.32 0.17  
Vitamin D type      
 D2 3 -0.02 -0.61 0.58 0.95 0.72 
 D3 14 0.09 -0.03 0.22 0.15  
T2D = type 2 diabetes; CVD = cardiovascular disease; CKD = chronic kidney disease; D2 = ergocalciferol; D3 = cholecalciferol; 25-OHD = 25 hydroxy vitamin D. 
  
Table 3: Meta-regression analysis to evaluate the association of potential modifiers of the 
effects of vitamin D supplementation on endothelial function 
Covariates Slope SE Q (df=1) P Value 
Baseline Systolic BP (mmHg) 0.002 0.003 0.60 0.43 
Baseline Diastolic BP (mmHg) 0.02 0.01 3.1 0.07 
Serum 25(OH)D at baseline (nmol/L) -0.003 0.002 2.47 0.11 
Change in serum 25-OHD after supplementation 
(nmol/L) 
-0.001 0.001 0.77 0.37 
Study Duration (weeks) 0.001 0.003 0.16 0.68 
Vitamin D Dose (IU) -0.0001 0.00001 0.12 0.71 
Age (years) -0.003 0.004 0.95 0.32 
BMI (kg/m2) 0.05 0.02 3.50 0.06 
Study Sample Size (N) -0.001 0.001 1.43 0.23 
Jadad Score -0.02 0.05 0.28 0.59 
BP = blood pressure; BMI = body mass index; N = number of study participants; 25-OHD = 25 hydroxy vitamin 
D. 
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